AstraZeneca plc (LON:AZN) had its price objective increased by Barclays PLC from GBX 6,000 ($77.72) to GBX 6,300 ($81.61) in a research report issued on Monday, MarketBeat reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. Barclays PLC’s target price indicates a potential upside of 22.69% from the stock’s current price.

Several other research firms also recently commented on AZN. Morgan Stanley restated an “overweight” rating and set a GBX 5,600 ($72.54) target price on shares of AstraZeneca plc in a research report on Friday, June 23rd. Shore Capital restated a “hold” rating on shares of AstraZeneca plc in a research report on Wednesday, June 21st. J P Morgan Chase & Co restated a “neutral” rating on shares of AstraZeneca plc in a research report on Monday, June 5th. Deutsche Bank AG restated a “buy” rating and set a GBX 5,700 ($73.83) target price on shares of AstraZeneca plc in a research report on Monday, June 5th. Finally, Liberum Capital restated a “buy” rating and set a GBX 5,500 ($71.24) target price on shares of AstraZeneca plc in a research report on Monday, June 5th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of GBX 5,267.68 ($68.23).

AstraZeneca plc (LON AZN) traded up 0.55% during midday trading on Monday, hitting GBX 5163.00. The company had a trading volume of 1,277,645 shares. The company’s 50 day moving average is GBX 5,259.89 and its 200-day moving average is GBX 4,769.91. AstraZeneca plc has a one year low of GBX 3,996.00 and a one year high of GBX 5,520.00. The company’s market cap is GBX 65.36 billion.

ILLEGAL ACTIVITY WARNING: This article was reported by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.americanbankingnews.com/2017/07/03/barclays-plc-boosts-astrazeneca-plc-azn-price-target-to-gbx-6300.html.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.